The absence of [kappa] free light chains
in the serum immunofixation electrophoresis prompted us to investigate the hypothesis of pleural synthesis of a [kappa] free light chain
linked to a pleural myelomatous involvement.
The assay kit that was used, namely "antiserum against human immunoglobulin light chains
", recognized ([kappa]) and lambda ([lambda]) light chains
both free and bound to heavy chains in intact immunoglobulins.
29) Accumulation of immunoglobulin light chains
within histiocytes may mimic the appearance of Gaucher cells or of the so-called pseudo-Gaucher cells seen in chronic myelogenous leukemia.
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains
Further laboratory results revealed that the patient had an elevated serum free kappa light chain
at 1080 mg/dL with a kappa/ lambda ratio of 800.
DiaSys's test is a unique, non-invasive dipstick format, measuring kappa and lambda light chains
separately, with minimal operator time, reduced processing time, antibody linked specificity, high sensitivity, with all reagents included.
Antibodies with human heavy and lambda light chains
are created by means of Kymouse HL strain while Kymouse HK produces antibodies with human heavy and kappa light chains
In rare cases, mutated monoclonal light chains
fail to bind to commercially available antibodies, leading to false-negative immunofluorescence staining.
Antibodies or immunoglobulins are proteins that consist of 2 identical heavy chains (HCs) and 2 identical light chains
But the growing clinical acceptance of a serum free light chain
assay has all but eliminated urine tests in identifying such plasma cell disorders as multiple myeloma (MM), smoldering myeloma, monoclonal gammopathy of undetermined significance (MGUS) and primary systemic amyloidosis (AL); and because the assay has proven to be more sensitive than IFE for detecting free or unbound immunoglobulin light chains
when it is used in conjunction with SPEP, up to 99% of myelomas can be detected.
Our patient had primary systemic (AL) amyloidosis, which occurs when a monoclonal population of plasma cells generates excess amyloidogenic immunoglobulin light chains
Edgewater, NJ) has patented a process for the production of an antibody or a fragment or functionalized fragment thereof using a transformed lower eukaryotic host containing an expressible DNA sequence encoding the antibody or (functionalized) fragment thereof, wherein the antibody or (functionalized) fragment thereof is derived from a heavy chain immunoglobulin of Camelidae and is devoid of light chains
, and wherein the lower eukaryotic host is a mould, preferably belonging to the genera Aspergillus or Trichoderma, or a yeast, preferably belonging to the yeast genera Saccharomyces, Kluyveromyces, Hansenula, or Pichia.